- Home
- GTN vs ENGN Comparison
GTN vs ENGN Comparison
Compare GTN & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GTN | ENGN |
|---|---|---|
| Founded | 1897 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Broadcasting | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.6M | 379.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GTN | ENGN |
|---|---|---|
| Price | $5.31 | $8.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $7.60 | ★ $22.71 |
| AVG Volume (30 Days) | ★ 1.1M | 528.5K |
| Earning Date | 11-07-2025 | 12-19-2025 |
| Dividend Yield | ★ 6.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $3,348,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.42 | N/A |
| P/E Ratio | $12.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.91 | $2.65 |
| 52 Week High | $6.31 | $11.14 |
Technical Indicators
Market Signals| Indicator | GTN | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 59.88 | 55.12 |
| Support Level | $4.57 | $7.77 |
| Resistance Level | $4.87 | $8.49 |
| Average True Range (ATR) | 0.22 | 0.61 |
| MACD | 0.08 | 0.07 |
| Stochastic Oscillator | 77.92 | 66.45 |
Price Performance
Historical ComparisonAbout GTN Gray Television Inc.
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.